Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Medulloblastoma (MB) is a common pediatric brain tumor.
• The hedgehog (Hh) signaling pathway is frequently activated in MB, driving tumor progression.
• Cholesterol biosynthesis's role in Hh-MB remains to be fully elucidated.

Purpose of the Study:

• To investigate the role of cholesterol biosynthesis in hedgehog pathway activity and Hh-MB progression.
• To evaluate statins as a therapeutic strategy for Hh-MB by targeting cholesterol biosynthesis.
• To validate cholesterol biosynthesis as a therapeutic target for Hh-MB.

Main Methods:

• Bioinformatic analysis of human biospecimens to correlate cholesterol biosynthesis with Hh-MB.
• Inhibition of cholesterol biosynthesis in medulloblastoma cells to assess Hh signaling alterations.
• In vivo studies using mice with genetic blockage of cholesterol biosynthesis and treatment with statins and/or vismodegib.

Main Results:

• Cholesterol biosynthesis was significantly upregulated in Hh-MB from both human and mouse samples.
• Inhibiting cholesterol biosynthesis reduced Hh pathway activity and medulloblastoma cell proliferation.
• Statins demonstrated efficacy in inhibiting medulloblastoma growth in vivo, with synergistic effects when combined with vismodegib.

Conclusions:

• Cholesterol biosynthesis is essential for Smoothened activity in the hedgehog pathway.
• Targeting cholesterol biosynthesis is a critical and promising therapeutic strategy for Hh-MB.
• Statins represent a viable therapeutic option for Hh-MB treatment, particularly in combination with other agents.